AbbVie Submits Regulatory Application to EMA for Subcutaneous Induction of SKYRIZI®️ in Crohn’s Disease
AbbVie announced the submission of a regulatory application to the European Medicines Agency (EMA) seeking approval for SKYRIZI® (risankizumab) for subcutaneous (SC) induction dosing...
FDA Approves Takeda’s First-in-Class Therapy MIMRYLO for Polycythemia Vera Following Robust Phase 3 Results
Takeda announced that the U.S. Food and Drug Administration (FDA) has approved MIMRYLO, a first-in-class therapy indicated for the treatment of polycythemia vera. Polycythemiavera is a rare, chronic...
Maharashtra FDA Withdraws Drug License Cancellation Order for Cipla C&F Unit Following Bombay High Court Rebuke
In a major regulatory development, the Maharashtra Food and Drug Administration (FDA) has withdrawn its order cancelingthe drug sale license of Cipla Pharma & Life Sciences Ltd’sCarrying and...
Orsini Partners with Priovant to Support Access to New Dermatomyositis Therapy LISRAYA
Orsini, a specialty pharmacy known for its work in rare disease care, has been named a specialty pharmacy partner for LISRAYA (brepocitinib), a newly...
‘Shwas Kavach’ Initiative Gains Government Recognition for AI-Enabled Last-Mile Medical Oxygen Network
Shwas Kavach, an initiative aimed at strengthening India's last-mile medical oxygen supply, has received recognition and support from the Office of the Principal Scientific Adviser (PSA) to...
India’s First AYUSH University to Build 100-Acre Permanent Campus in Kurukshetra, Haryana
The Ministry of Ayush announced the development of the permanent campus for India’s first dedicated AYUSH University, sprawling across nearly 100 acres in Fatehpurvillage, Kurukshetra, Haryana. First announced...
